Treatment Approaches to Esophagogastric Junction Tumors

Yukinori Kurokawa\textsuperscript{a}  Mitsuru Sasako\textsuperscript{b}  Yuichiro Doki\textsuperscript{a}

\textsuperscript{a}Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, and
\textsuperscript{b}Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, Nishinomiya, Japan

Introduction

The incidence of esophagogastric junction (EGJ) tumors has rapidly increased [1]. Although EGJ tumors may comprise any histological type, the majority are adenocarcinomas. Adenocarcinomas involving the EGJ are usually classified into three categories according to the Siewert system based on their epicenter [2]. Siewert type I tumors are located 1–5 cm above the EGJ and usually arise from an area of intestinal metaplasia area in the esophagus, i.e., Barrett’s esophagus. Siewert type II tumors, located 1 cm above to 2 cm below the EGJ, represent true carcinoma of the EGJ, arising from the epithelium of the cardia or short segments of intestinal metaplasia at the EGJ. Siewert type III tumors represent subcardial gastric cancer located 2–5 cm below the EGJ with invasion of the distal esophagus.

EGJ tumors portend poor survival [3, 4]. Although surgery is the most effective curative treatment, the proportion of R1 or R2 resection is comparatively high. Even with R0 resection, the recurrence rate within 2 years is also high. To improve the R0 resection rate and long-term outcomes, perioperative treatment has been attempted. In this review, we outline the characteristics, surgical approaches, and adjuvant treatments for EGJ tumors.
Characteristics of EGJ Tumors

The characteristics of EGJ adenocarcinomas according to the Siewert classification are shown in table 1 [5–7]. Siewert type I tumors are usually associated with intestinal metaplasia and occur more often in males. Siewert type III tumors involve intestinal metaplasia less often, and there is a higher proportion of the undifferentiated type. Siewert type II tumors fall between types I and III in most characteristics, but the proportion of human epidermal growth factor receptor 2 positivity in type II tumors is higher than in types I and III [8]. Although there is almost an even distribution among these three types in Western countries, there are very few Siewert type I patients in Eastern countries [7, 9, 10]. This discrepancy is probably due to differences in the prevalence of Helicobacter pylori infection and gastroesophageal reflux disorder.

The prognosis of EGJ tumors is significantly related to the extent of lymph node involvement, which is associated with lymphatic drainage from the tumor [11]. EGJ tumors, whether of the adenocarcinoma or squamous cell carcinoma type, have the potential of metastasizing to the mediastinal, perigastric, and abdominal para-aortic lymph nodes. Details on the incidence of metastasis to regional lymph nodes of the stomach by Siewert type II tumors are shown in table 2 [7, 12, 13]. Lymphatic flow is mainly directed toward the abdomen; most patients with pathological node-positive disease have metastases to pericardial and lesser curvature nodes (Nos. 1, 2, 3, 7) [6]. Other perigastric nodes (Nos. 4sa, 4sb, 4d, 5, 6) have an extremely low incidence of metastasis. Metastasis to the abdominal para-aortic area (No. 16a2) is observed in approximately 15% of EGJ patients, representing the most frequent site of nodal recurrence [7, 12]. Considering the high proportion of metastases to the lower mediastinal lymph nodes [14], dissection of this area is necessary for treatment of EGJ tumors of any type. In contrast, nodal metastasis to the upper or middle mediastinum from Siewert type II or III tumors is relatively rare [5]; therefore, thorough dissection of this area via thoracotomy for type II and III tumors is not necessary. The most frequent type of recurrence is hematogenous spread to the liver and lung, followed by para-aortic lymph node involvement [15]. Peritoneal recurrence is rare with Siewert type I or II tumors [14] but common with type III tumors [16].

Table 1. Characteristics of EGJ junction adenocarcinomas according to the Siewert classification

<table>
<thead>
<tr>
<th>Siewert type</th>
<th>I</th>
<th>II</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>male &gt;&gt; female</td>
<td>male &gt; female</td>
<td>male &gt; female</td>
</tr>
<tr>
<td>Intestinal metaplasia</td>
<td>mostly</td>
<td>rare</td>
<td>very rare</td>
</tr>
<tr>
<td>Percentage of positive nodes</td>
<td>50</td>
<td>60–70</td>
<td>80</td>
</tr>
</tbody>
</table>

Histological grading is based on the International Union Against Cancer (UICC) Tumor-Node-Metastasis (TNM) Classification, ed 6.

Table 2. Incidence of metastasis to regional lymph nodes of the stomach by Siewert type II tumors in three Japanese studies

<table>
<thead>
<tr>
<th>Lymph node stationa</th>
<th>National Cancer Center Hospital [12], %</th>
<th>National Cancer Center Hospital Eastb [7], %</th>
<th>Osaka University Clinical Research Group [13], %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>38.2 (86/225)</td>
<td>42.1 (61.6 (53/86)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>23.1 (52/225)</td>
<td>20.6 (31.4 (27/86)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>35.1 (79/225)</td>
<td>23.4 (52.3 (45/86)</td>
<td></td>
</tr>
<tr>
<td>4sa</td>
<td>4.0 (9/225)</td>
<td>5.6 (7.0 (6/86)</td>
<td></td>
</tr>
<tr>
<td>4sb</td>
<td>1.3 (3/225)</td>
<td>2.8 (3.5 (3/86)</td>
<td></td>
</tr>
<tr>
<td>4d</td>
<td>0.0 (0/169)</td>
<td>1.2 (0.0 (0/86)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>0.6 (1/169)</td>
<td>3.5 (1.2 (1/86)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1.2 (2/169)</td>
<td>2.6 (3.5 (3/86)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>20.9 (47/225)</td>
<td>22.4 (25.9 (22/85)</td>
<td></td>
</tr>
<tr>
<td>8a</td>
<td>6.2 (14/225)</td>
<td>6.7 (8.5 (7/82)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>10.2 (23/225)</td>
<td>13.3 (8.8 (7/80)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>4.1 (6/147)</td>
<td>3.9 (2.9 (2/69)</td>
<td></td>
</tr>
<tr>
<td>11p</td>
<td>11.1 (25/225)</td>
<td>14.0 (20.5 (15/73)</td>
<td></td>
</tr>
<tr>
<td>11d</td>
<td>6.9 (12/173)</td>
<td>6.3 (N/A)</td>
<td></td>
</tr>
<tr>
<td>12a</td>
<td>0.0 (0/102)</td>
<td>0.0 (N/A)</td>
<td></td>
</tr>
</tbody>
</table>

a Based on the Japanese Classification of Gastric Carcinoma, ed 2 (English).
b The number of patients with positive nodes by station number is not available (N/A).
Surgery for EGJ Tumors

The surgical approach is mainly based on tumor location, i.e. Siewert classification. A Dutch group has conducted a randomized controlled trial comparing the right transthoracic and transhiatal approaches for Siewert type I and II tumors [17]. Perioperative morbidity was higher with the transthoracic approach. Although there were no statistically significant differences in overall survival in the entire study population between the two groups, there was a clear trend towards improved survival with the transthoracic approach. In subgroup analysis based on the Siewert classification, the advantage in 5-year overall survival with the transthoracic approach versus the transhiatal approach was as large as 14% for type I patients (n = 90), and –4% for type II patients (n = 115) [18]. Due to an inadequate sample size, this study could not show any statistically significant differences, but the results strongly suggest that thorough mediastinal dissection via a right thoracotomy is necessary for Siewert type I but not for type II tumors.

A Japanese group conducted another randomized controlled trial for mainly Siewert type II and III tumors, comparing the left transthoracic and transhiatal approaches [19]. This study demonstrated that there was no survival benefit and higher morbidity associated with the transthoracic approach. The transthoracic approach also aggravated weight loss, symptoms, and respiratory functions in comparison to the transhiatal approach [20]. Subgroup analysis showed no survival benefit for Siewert type II patients with the transthoracic approach. The transhiatal approach was associated with better survival than the transthoracic approach for Siewert type III patients.

Based on these two trials, transthoracic esophagectomy with resection of the proximal stomach should be performed for EGJ type I tumors. The transthoracic approach enables lymph node dissection of the middle mediastinum, which is not accessible through the esophageal hiatus. For EGJ type II or III tumors, total gastrectomy with transhiatal resection of the distal esophagus is recommended. The thoracotomy-sparing transhiatal approach is less invasive and associated with lower morbidity and mortality. However, the transhiatal approach can lead to difficulties in obtaining sufficient margins if the tumor has invaded the distal esophagus 3 cm beyond the EGJ.

Perioperative Treatment for EGJ Tumors

In the late 1990s, two Western randomized controlled trials were conducted to evaluate adjuvant treatment for gastric and EGJ cancer. One was the INT 0116 trial comparing postoperative chemoradiotherapy (CRT) with 5-fluorouracil and leucovorin to surgery alone. Although CRT was associated with a large survival benefit, 90% of the patients had received insufficient lymph node dissection (D0 or D1) [21]. In addition, the MAGIC trial, which compared perioperative chemotherapy with epirubicin, cisplatin, and 5-fluorouracil to surgery alone [22], showed a significant survival benefit with perioperative chemotherapy (5-year overall survival, 36.3% in the CRT group and 23.0% in the surgery-alone group; p = 0.009). However, this trial also included a high proportion of patients who received insufficient D0/D1 dissections. In fact, the surgery-alone group in these trials had much shorter survival than the surgery-alone group in a Japanese randomized trial with a similar tumor stage distribution [23, 24].

In the 2000s, a Dutch CROSS randomized controlled trial evaluated preoperative CRT using carboplatin and paclitaxel for esophageal or EGJ tumors [25]. In this study, 178 patients were randomly assigned to CRT followed by surgery, and 188 to surgery alone. The preoperative CRT group had a 23% higher R0 resection rate than the surgery-alone group, and the pathological complete response rate in the preoperative CRT group reached 29%. Overall survival was significantly better in the preoperative CRT group (5-year overall survival, 47% in the CRT group and 34% in the surgery-alone group; p = 0.003). Although the survival benefit was more prominent for the squamous cell carcinoma subset, patients with adenocarcinoma of the esophagus, including EGJ tumors, also benefited significantly from the CRT (hazard ratios for death: 0.453 in squamous cell carcinoma and 0.732 in adenocarcinoma). Based on the results of this trial, preoperative CRT became the standard for resectable esophageal and EGJ tumors in the West, although it was not a comparison between preoperative CRT and neoadjuvant chemotherapy.

In contrast, there were two large-scale randomized controlled trials with over 1,000 patients each evaluating postoperative chemotherapy for resectable gastric or EGJ tumors in East Asia. One was the Japanese ACTS-GC trial, which compared postoperative chemotherapy with S-1 for 1 year with surgery alone involving D2 dissection [26]. It showed a significant improvement in overall survival in the postoperative chemotherapy group (p = 0.003). The recently updated results showed a 10.6% improvement in
5-year overall survival (71.7% in the postoperative chemotherapy group, 61.1% in the surgery-alone group) [27]. The other study was the Korean CLASSIC trial, which compared adjuvant chemotherapy group with capecitabine plus oxaliplatin for 6 months with surgery alone involving D2 dissection. The postoperative chemotherapy group had a 15% improvement in 3-year disease-free survival (74% in the postoperative chemotherapy group, 59% in the surgery-alone group) [28]. Both trials demonstrated a significant survival benefit with postoperative chemotherapy, which led to the establishment of new standard of care for stage II or III gastric and EGJ tumors in East Asia. However, since the proportion of EGJ tumors among all patients recruited for these Asian trials was small, it is unclear whether these results can be directly applied to treatment for EGJ tumors, which is not the same as gastric cancer in tumor biology.

In Korea, the recent ARTIST randomized controlled trial evaluating the addition of radiation therapy to postoperative chemotherapy with capecitabine plus cisplatin for gastric or EGJ tumors after D2 dissection did not show a significant benefit with the addition of radiation to postoperative chemotherapy (3-year disease-free survival, 78% in the CRT group and 74% in the chemotherapy group; \( p = 0.09 \)) [29]. It indicated that the addition of radiation therapy to neoadjuvant or postoperative chemotherapy as commonly performed in the West may not be effective for EGJ tumors in East Asia, where most surgeons are familiar with extensive lymph node dissection that leads to good local tumor control. Actually, the largest retrospective case series in Japan for Siewert type II tumors revealed that the local recurrence rate was very low and that the most common type of recurrence was hematogenous [12].

Most of above-mentioned trials included patients with esophageal and gastric cancers, not just EGJ tumors alone. A randomized trial involving only patients with Siewert type I–III EGJ tumors was conducted in Germany [30]. This study evaluated the addition of radiation therapy to preoperative 5-fluorouracil, cisplatin, and leucovorin, but it was prematurely closed due to low accrual. The preoperative CRT group had a relatively high pathological complete response rate of 15.6% compared to 2.0% in the preoperative chemotherapy group. Although preoperative CRT resulted in a 20% increase in 3-year overall survival, the difference between the two groups was not statistically significant. Furthermore, postoperative mortality in the preoperative CRT group (10.2%) was much higher than in the preoperative chemotherapy group (3.8%). Thus, the necessity of radiation therapy in addition to chemotherapy remains unknown.

Conclusions

Siewert type II tumors can be treated with a transthoracic approach, whereas right thoracotomy and lymph node dissection of the middle mediastinum is necessary for Siewert type I tumors. Preoperative CRT is the current standard of care in the West for the treatment of cancer of the EGJ, while surgery followed by postoperative chemotherapy is currently the only evidence-based treatment available in the East. Given the less favorable outcome when compared with cancer of the distal stomach and relatively low incidence of local recurrence, clinical trials exploring the impact of neoadjuvant chemotherapy may be warranted in the future for cancer of the EGJ in the East.

References


